Equillium. has been granted a patent for methods and compositions targeting ?c-family cytokines to treat alopecia and related disorders. The patent details a ?c cytokine antagonist peptide that inhibits specific interleukins, potentially reducing the severity of immune-mediated hair loss. GlobalData’s report on Equillium gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Equillium, Molecular diagnosis biomarkers was a key innovation area identified from patents. Equillium's grant share as of July 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating alopecia using ?c cytokine antagonists
The granted patent US12030936B2 outlines a method for treating alopecia-related disorders through the administration of a specific composition. This composition includes a ?c cytokine antagonist peptide, which is derived from the ?c box D-helix regions of at least two interleukin (IL) proteins. The core sequence of this peptide is 11 amino acids long, specifically identified as SEQ ID NO: 1. The method aims to inhibit signaling by IL-2, IL-9, and/or IL-15, as well as to decrease circulating levels of IL-6 and/or IFN? in individuals experiencing alopecia or immune-mediated hair loss. The administration of this peptide is intended to ameliorate or reduce the severity of these conditions.
Further claims in the patent detail variations of the ?c cytokine antagonist peptide, including those that consist of the sequence of SEQ ID NO: 1, as well as peptides comprising 19 to 50 amino acids. The patent also describes the potential for the peptide to include conjugates at various positions, such as the N-termini or C-termini, with additional moieties like bovine serum albumin, antibodies, or Poly Ethylene Glycol. Additionally, the method allows for the incorporation of a hydrocarbon linker element and specifies that the composition can be formulated for various delivery methods, including topical, oral, or parenteral routes.
To know more about GlobalData’s detailed insights on Equillium, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
